Lowering Global Mortality
COVID-19 has infected over 400,000 individuals and killed over 18,000 world wide. The leading cause of death is reported to be from pneumonia as a result of COVID-19. This is our expertise and we are looking to help!
How We Plan On Lowering Global Mortality?
Immune Diagnostics is an industry leader in Streptococcus pneumoniae microbiology and related analytics. We provide analytical tools and services to vaccine developers, public health organizations, and researchers dedicated to reducing global morbidity and mortality from pneumococcal pneumonia and related diseases. These are largely preventable diseases that have been reduced in developed countries by use of effective vaccine programs.
Our leading products include fully human monoclonal antibodies against pneumococcal capsular polysaccharide serotypes, for which we hold the worldwide exclusive license. Immune Diagnostics is currently developing a broad range of reagents, standards and controls to improve vaccine and drug development, manufacturing quality control and a range of other applications. We also offer custom high-throughput serotyping assays. The serotyping technology is used to generate pneumococcal carriage data across large populations to identify the most prevalent pathogens being carried. This data is essential to developing and deploying the most effective vaccines.
We are looking to work with an organization that will aid us with our clinical trials for our fully-human antibodies. This would allow us provide all the nations effected by COVID-19 a real chance at lowering the mortality rate. If you have any questions or would like to work together please contact us. It is our hope to move as quickly as possible.